[3]Oliveira M, Pominchuck D, Nowecki Z, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. 2022 SABCS. Abstract GS3-02. [4]Oliveira ...
[3]Oliveira M, Pominchuck D, Nowecki Z, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-...
参考文献 [1].Oliveira M, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. 2022 SABCS. CT GS3-02. [2].Sung H, Ferlay J, Siegel R...
▌参考文献: Mafalda Oliveira, et al. Dynamics of ESR1m ctDNA in patients with ER+ HER2– metastatic breast cancer receiving camizestrant or fulvestrant Exploratory analysis from the SERENA-2 trial. ESMO Breast Cancer 2024, Abstract 2MO
[1].Oliveira M, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 tr...
[3]Oliveira M, Pominchuck D, Nowecki Z, et al Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. 2022 SABCS. Abstract GS3-02. ...
▌参考文献: Mafalda Oliveira,et al.Dynamics of ESR1m ctDNA in patients with ER+HER2–metastatic breast cancer receiving camizestrant or fulvestrant Exploratory analysis from the SERENA-2 trial.ESMO Breast Cancer 2024,Abstract 2MO
Mafalda Oliveira, et al. Dynamics of ESR1m ctDNA in patients with ER+ HER2– metastatic breast cancer receiving camizestrant or fulvestrant Exploratory analysis from the SERENA-2 trial. ESMO Breast Cancer 2024, Abstract 2MO...
Mafalda Oliveira, et al. Dynamics of ESR1m ctDNA in patients with ER+ HER2– metastatic breast cancer receiving camizestrant or fulvestrant Exploratory analysis from the SERENA-2 trial. ESMO Breast Cancer 2024, Abstract 2MO (来源:《肿瘤瞭望》编辑部) ...
Medical oncologists discuss oral SERDs, with a focus on the SERENA-2 trial looking at camizestrant in patients with advanced ER+/HER2- breast cancer. EP: 1.Testing for ESR1 Mutations in Breast Cancer EP: 2.Overcoming Challenges in Biomarker Testing in Breast Cancer EP: 3.PADA-1 Trial: ...